Ascletis Completes Enrollment in Phase II Study for Diabetes Drug ASC30

Ascletis Completes Enrollment in Phase II Clinical Trial

Ascletis Pharma Inc. has reached a significant milestone by completing participant enrollment in its 13-week Phase II study of ASC30, a promising oral small molecule GLP-1 receptor agonist. This trial, conducted in the United States, aims to evaluate the efficacy, safety, and tolerability of ASC30 in individuals diagnosed with type 2 diabetes mellitus (T2D). With this study, Ascletis is looking to strengthen its position in the diabetes treatment sector, expanding on its initial focus on obesity-related therapies.

Overview of the Phase II Study

The Phase II study, registered under the identifier NCT07321678, has enrolled 100 participants across multiple sites in the U.S. This randomized, double-blind, placebo-controlled trial will monitor the effects of ASC30 administered as once-daily tablets. The primary endpoint being measured is the mean change in HbA1c from baseline over 13 weeks, alongside secondary endpoints evaluating fasting blood glucose, body weight changes, and overall safety and tolerability of the drug.

Efficacy and Potential

CEO Jinzi Jason Wu accentuated the potential of ASC30, suggesting it could be a best-in-class oral GLP-1 therapy for obesity. The results from this Phase II trial are anticipated in the third quarter of 2026. Positive outcomes could pave the way for a more robust entry into the diabetes treatment market.

Future Developments

In December 2025, Ascletis announced encouraging preliminary results from its previous Phase II study focused on obesity, which highlighted ASC30’s efficacy and tolerability. Following these results, the company is optimistic about gaining FDA clearance to initiate Phase III trials for the obesity indication toward the end of the third quarter of 2026.

Unique Characteristics of ASC30

ASC30 is notably distinguished as both a first and only investigational small molecule GLP-1 receptor agonist capable of being dosed once daily orally, with additional dosing options available once monthly or quarterly via subcutaneous injection. This versatile administration creates avenues for improved patient compliance and management of related metabolic diseases.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is an innovative biotech company committed to developing transformative therapeutics for metabolic diseases. The company's proprietary technologies, including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), enable rapid and effective drug development. Some notable candidates in their pipeline include ASC36, an amylin receptor peptide agonist, and ASC35, a GLP-1/GIP dual peptide agonist designed for chronic weight management.

Conclusion

The completion of enrollment in the Phase II study marks a pivotal step for Ascletis Pharma and highlights the ongoing commitment to advancing diabetes treatment options. As data from this study is set to be unveiled in the coming months, stakeholders are keenly awaiting the implications for both ASC30 and the broader diabetes therapeutic landscape.